Shares of LivaNova PLC (NASDAQ:LIVN) have been given an average rating of “Buy” by the eight brokerages that are presently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $128.75.
Several research firms have recently issued reports on LIVN. Needham & Company LLC restated a “buy” rating and set a $120.00 price objective (down previously from $135.00) on shares of LivaNova in a report on Wednesday, February 27th. BidaskClub upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a report on Wednesday. BTIG Research restated a “hold” rating on shares of LivaNova in a report on Tuesday, March 5th. Finally, Zacks Investment Research upgraded shares of LivaNova from a “strong sell” rating to a “hold” rating in a report on Wednesday, January 2nd.
In related news, Director Daniel Jeffrey Moore sold 1,500 shares of the stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $100.44, for a total value of $150,660.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Alistair Simpson sold 450 shares of the stock in a transaction that occurred on Thursday, January 10th. The stock was sold at an average price of $90.10, for a total transaction of $40,545.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,950 shares of company stock worth $472,350. 0.41% of the stock is owned by corporate insiders.
Shares of LIVN traded up $0.32 during mid-day trading on Friday, hitting $97.25. 349,000 shares of the company traded hands, compared to its average volume of 503,784. LivaNova has a 1-year low of $79.96 and a 1-year high of $131.54. The company has a quick ratio of 0.76, a current ratio of 1.07 and a debt-to-equity ratio of 0.09. The company has a market cap of $4.67 billion, a P/E ratio of 30.68, a price-to-earnings-growth ratio of 2.90 and a beta of 0.87.
LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, February 27th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.05. LivaNova had a negative net margin of 17.11% and a positive return on equity of 9.64%. The firm had revenue of $297.00 million for the quarter, compared to the consensus estimate of $294.98 million. During the same quarter in the prior year, the company posted $0.88 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, research analysts anticipate that LivaNova will post 3.22 EPS for the current fiscal year.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
See Also: Futures Contract
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.